Seminars in Hematology
Volume 45 , Pages S7-S10 , July 2008

Bendamustine in Chronic Lymphocytic Leukemia and Refractory Lymphoma

  • Mathias J. Rummel

      Affiliations

    • Corresponding Author InformationAddress correspondence to Mathias J. Rummel, MD, PhD, Chief, Department of Hematology, Hospital of the Justus-Liebig-University of Giessen, Klinikstr. 36, 35392 Giessen, Germany

References 

  1. Ponisch W, Niederwieser D. Bendamustine in the treatment of multiple myeloma: Results and future perspectives. Semin Oncol. 2002;29:23–26
  2. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone—A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;132:205–212
  3. von Minckwitz G, Chernozemsky I, Sirakova L, et al. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): A phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs. 2005;16:871–877
  4. Schmittel A, Knodler M, Hortig P, Schulze K, Thiel E, Keilholz U. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer. 2007;55:109–113
  5. Bokemeyer C, Kollmannsberger C, Harstrick A, et al. Treatment of patients with cisplatin-refractory testicular germ-cell cancer (German Testicular Cancer Study Group (GTCSG)). Int J Cancer. 1999;83:848–851
  6. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): Results of an international phase III study. Blood. 2007;110:609a;(abstr 2043)
  7. Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001;19:3611–3621
  8. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspases. Haematologica. 2002;87:33–43
  9. Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, et al. SDX-105 (bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood. 2003;102:640a;(abstr 2363)
  10. Leoni LM, Bailey B, Niemeyer C, Reifert J, Bendall H, Dauffenbach L, et al. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res. 2004;45:1215;(abstr)
  11. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317
  12. Rummel MJ, Al Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:3383–3389
  13. Williams ME, Cohen P, Tulpule A, et al. A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2006;24:429s;(abstr 7528)
  14. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204–210
  15. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002;20:3262–3269
  16. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas—First interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood. 2007;110:120a;(abstr 385)
  17. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002;29:12–14
  18. Rummel MJ, Mitrou PS, Hoelzer D. Bendamustine in the treatment of non-Hodgkin's lymphoma: Results and future perspectives. Semin Oncol. 2002;29:27–32
  19. Anger G, Fink R, Fleischer J, et al. Vergleichsuntersuchungen zwischen Cytostasan und Cyclophosphamid bei der chronischen Lymphadenose, dem Plasmozytom, der Lymphogranulomatose und dem Bronchialkarzinom. Dtsch Gesundheitswesen. 1975;30:1280–1285
  20. Blumenstengel K, Schmalenberg H, Fricke HJ, Kath R, Hoè€ken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia (CLL). Onkologie. 1997;20:549;(abstr)
  21. Bremer K. Bendamustine: Effective salvage chemotherapy in pretreated low grade non-Hodgkin's lymphomas. Ann Oncol. 1999;10:127
  22. Kath R, Blumenstengel K, Fricke HJ, Hoffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001;127:48–54
  23. Aivado M, Schulte K, Henze L, Burger J, Finke J, Haas R. Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectives. Semin Oncol. 2002;29:19–22

 STATEMENT OF CONFLICT OF INTEREST: No significant financial relationships to disclose.

PII: S0037-1963(08)00122-4

doi: 10.1053/j.seminhematol.2008.07.006

Seminars in Hematology
Volume 45 , Pages S7-S10 , July 2008

Article Tools

* Image Usage & Resolution